Thailand medical device registration — non-IVD device approval with the Thai FDA

Thailand Medical Device Registration: Non-IVD Devices With and Without a US FDA 510(k)

Thailand medical device registration splits into two very different exercises depending on one fact: whether the device already holds a US FDA 510(k) clearance. A cleared device can take an abridged evaluation that skips part of the Thai FDA’s specialist review. A device without one goes through full evaluation and must carry its own technical evidence. Both routes end in the same licence, but the dossier, the timeline and the work are not comparable. This guide sets out both for non-IVD devices, and the sequencing decision that sits behind them.
DefinitionThailand medical device registration is the process under the Medical Device Act B.E. 2551 (2008), as amended by the Medical Device Act (No. 2) B.E. 2562 (2019), by which a device is listed, notified or licensed with the Medical Device Control Division of the Thai FDA before it may lawfully be imported, manufactured or sold in Thailand.

What Thailand medical device registration requires

Every non-IVD medical device sold in Thailand needs two things: a Thai establishment licence held by a local entity, and a product approval matched to the device’s risk class. Neither substitutes for the other. A foreign manufacturer cannot hold either directly, so the structure has to exist before anyone files a dossier.

The two permissions, and why people confuse them

The establishment licence authorises a Thai entity to manufacture, import or sell medical devices. It sits with the company, it is valid for five years, and only a Thai national or an entity established in Thailand may apply for it. The product approval attaches to the device itself and names that licence holder.

That split catches out most first-time entrants. The registration belongs to the licence holder, not to the manufacturer. So if a foreign manufacturer registers through a distributor and the relationship later ends, the registration does not travel with the manufacturer. It stays with the licence holder. Groups that intend to build a Thai business rather than test the market should hold the establishment licence in their own Thai entity from the outset.

How Thailand classifies a non-IVD medical device

Thailand classifies devices into four risk classes, aligned with the ASEAN Medical Device Directive. Class 1 is lowest risk, Class 4 highest. The class decides the pathway: Class 1 devices go through listing, Class 2 and Class 3 through notification, and Class 4 requires a full licence. Classification is the first decision in any matter and it drives everything after it.

Class Risk Pathway What the Thai FDA looks at
Class 1 Low Listing Labelling, instructions for use, product specification, device description, materials, declaration of conformity and letter of authorisation
Class 2 Low to moderate Notification Full CSDT technical file
Class 3 Moderate to high Notification Full CSDT technical file, with closer scrutiny of clinical evidence
Class 4 High or life-sustaining Licensing Complete CSDT dossier and full Thai FDA review

One practical point on Class 1. Since January 2025 the Thai FDA has operated an auto-approval process for qualifying Class 1 professional-use devices that appear on its Positive List, identified by GMDN code. Where a device genuinely sits on that list, the listing issues on submission. Where it does not, the assumption that Class 1 means fast does not belong in the project plan.

Key takeawayClassification is a legal determination, not a marketing description. Where a device sits near a class boundary, the difference between Class 2 and Class 3, or between a device and a general wellness product, changes the dossier, the review and the launch date. Settle it in writing before the dossier is built, because reclassification mid-review restarts the exercise.

Route one: Thailand medical device registration with a US FDA 510(k)

A device cleared by the US FDA can use the abridged evaluation route. This route opens to any device that a recognised regulatory agency has already cleared, including the US FDA, EU notified bodies, Australia’s TGA, Japan’s MHLW, Health Canada and WHO prequalification. It exempts certain documents and allows the application to bypass part of the specialist review, which is where most of the review time is spent.

What the 510(k) actually buys

  • Exemption from parts of the technical file, typically the summary verification and validation documentation, the risk analysis and the waste disposal documentation
  • Avoidance of specialist review for the exempted elements, which is the single largest saving in elapsed time
  • A credible answer to the reviewer’s core question, because a recognised agency has already assessed the device
  • A smoother path on higher-risk classes, where Thai reviewers scrutinise clinical and performance evidence most closely

What it does not buy

Three limits are worth stating plainly, because each of them has derailed a launch plan.

First, the clearance must be at least one year old. The abridged route requires the reference approval to have been in place for a minimum of one year. A manufacturer that obtained its 510(k) three months ago cannot use the abridged route yet, which inverts the intuition that a fresh clearance means a fast Thai entry. For a device cleared recently, the honest comparison weighs filing a Thai full evaluation now against waiting out the seasoning period.

Second, the clearance must cover the same device. Thai reviewers compare intended use, labelling and packaging against what the reference agency cleared. A 510(k) held for a different configuration, a different indication or an earlier generation of the product does not carry across, and asserting otherwise invites a question round that costs more time than the exemption saved.

Third, a 510(k) is a finding of substantial equivalence to a predicate device, not an approval on safety and efficacy in the sense a Thai reviewer may assume. The abridged route treats it as reference-agency approval, so this rarely matters procedurally. It matters when the reviewer asks what clinical evidence supports a claim, and the answer is that the predicate carried it.

Key takeawayConfirm three things before planning around a 510(k): the clearance date is more than a year ago, the cleared device matches what you will sell in Thailand on intended use and labelling, and the clearance is held by or properly licensed to the entity that will appear on the Thai dossier. If any one fails, the abridged route is not available and the plan should be rebuilt around full evaluation.

Route two: Thailand medical device registration without a 510(k)

A device with no reference-agency approval goes through full evaluation. This is the standard route and it is entirely workable. Since 2024 the Thai FDA has reduced what full evaluation requires, and reference-agency approval evidence is no longer among the documents demanded. The device must carry its own technical case instead.

What the dossier has to prove

The Common Submission Dossier Template is the format, and for Class 2, 3 and 4 devices it must stand on its own. The reviewer must reach a conclusion no other regulator has reached for them, so the evidence has to be complete rather than merely present.

  1. Device description and intended use. Written in the terms the Thai FDA uses, matched to the GMDN code and consistent across the labelling, the instructions for use and the application form.
  2. Risk analysis. A full risk management file. This is the element the abridged route would have exempted, and it is the element reviewers read hardest on full evaluation.
  3. Verification and validation. Design validation, bench testing, biocompatibility and electrical safety as the device type requires, mapped to recognised standards.
  4. Clinical or performance evidence. Proportionate to the class. Class 3 and Class 4 devices attract genuine scrutiny here, and you must argue a literature-based case rather than merely attach it.
  5. Quality system evidence. An ISO 13485 certificate, a TCAS 13485 certificate or a GMP certificate, reflecting the Good Manufacturing Practice B.E. 2566 (2023) requirements.
  6. Labelling and instructions for use in Thai. Translated and consistent with the claims made in the dossier, which is a more common failure point than the technical content.
  7. Letter of authorisation. From the manufacturer to the Thai establishment licence holder, in the form the Thai FDA accepts.

The documentation point nobody has settled

Published guidance disagrees about whether a Certificate of Free Sale from the country of manufacture remains mandatory. Some sources state that the Thai FDA dropped it when it cut the documentation load. Others continue to list it, and practitioners report that reviewers still ask for market-authorisation evidence on higher-risk classes. We flag this rather than resolve it: confirm the position with the Medical Device Control Division for the specific class and device before building a launch plan around its absence. A manufacturer whose home-country certificate has a short validity period, as is common for Chinese manufacturers, should raise the point early rather than discover it at submission.

Thailand medical device registration: the two routes compared

The choice is not usually a choice. A device either has a qualifying reference approval or it does not. What the comparison decides is the project plan, and specifically whether obtaining a reference approval first is worth the delay it adds.

Feature With a US FDA 510(k) Without a 510(k)
Thai pathway Abridged evaluation Full evaluation
Eligibility Cleared by a recognised agency for at least one year, same device Open to any device meeting the substantive requirements
Risk analysis in the dossier May be exempt Required, and read closely
Verification and validation summary May be exempt Required
Specialist review Partially bypassed Full
Clinical evidence burden Largely carried by the reference decision Carried by the dossier
Relative timeline Shorter, materially so on Class 3 and Class 4 Longer; the authority works to a defined maximum decision period that extends for the highest class
Main failure mode Mismatch between the cleared device and the Thai device Thin risk file or unargued clinical evidence
Establishment licence Required Required
Thai labelling Required Required

A third route worth knowing about

Devices approved by Singapore’s Health Sciences Authority can use the reliance route, provided the Thai submission is identical to the Singapore CSDT file and the Singapore registrant consents to the HSA sharing its documentation with the Thai FDA. Qualifying applications bypass the specialist review step. For groups already selling in Singapore, this is frequently the fastest way into Thailand and it is routinely overlooked.

Sequencing: should you obtain a reference approval first?

For most manufacturers without a 510(k), the answer is no. Filing a Thai full evaluation now is usually faster than obtaining a US clearance and then waiting the required year before the abridged route opens. The exception is a manufacturer that already has a US or Singapore submission in flight, where the arithmetic changes.

The reasoning is worth setting out, because the instinct to “get the FDA clearance first” is strong and often wrong for a Thailand-only objective. A 510(k) submission has its own preparation and review period. Add the one-year seasoning requirement before the abridged route becomes available, and then add the Thai review itself. Against that, a full evaluation filed today runs a single Thai review with no waiting period in front of it. Unless the manufacturer wants the US market for its own sake, sequencing through Washington to reach Bangkok costs more time than it saves.

The calculus flips when a reference filing is already under way. A manufacturer whose Singapore HSA registration will complete shortly should weigh the reliance route, because it is available immediately on approval with no seasoning period, and it removes the specialist review step entirely. That is the one case where waiting is usually right.

Key takeawayDecide the Thai pathway on the approvals you hold today, not on the ones you intend to obtain. The seasoning requirement means a clearance obtained for the purpose of easing Thai entry does not help for a year, by which time a full evaluation filed at the outset would in most cases have concluded.

Thailand medical device registration: what changes in 2026

Two developments matter for anyone planning a filing this year. The Thai FDA has issued a new announcement on the registration of medical device manufacturing facilities, and it has modernised the establishment registration forms. Both take effect in May 2026 and both change the paperwork rather than the substance.

Development Status What it means in practice
Announcement on the criteria, procedures and conditions for registration of medical device manufacturing facilities Issued 15 January 2026, published in the Royal Gazette on 2 March 2026, effective May 2026 Facility assessment moves from a document checklist toward alignment between the facility’s operations, its technical capability and the risk class of the products handled
Revised establishment registration forms Mandatory from 1 May 2026 Updated forms for manufacture, import and sale, including standalone software notification and storage locations
Good Manufacturing Practice B.E. 2566 (2023) and Good Importing and Sales Practice B.E. 2566 (2023) In force Moderate and high-risk manufacturers must hold GMP, TCAS 13485 or ISO 13485 certification; low-risk manufacturers are exempt from certification but must still meet the standards

Applications prepared on the superseded forms after the May 2026 cut-off meet rejection on filing rather than review, which costs a full cycle. Anyone with a dossier in preparation should confirm the current form set before submission.

Where these matters go wrong

Failure mode How it shows up How it is avoided
Registration held by the distributor The relationship ends and the manufacturer has no registration Hold the establishment licence in your own Thai entity, or paper the transfer mechanics before appointing a distributor
Assuming a recent 510(k) unlocks the abridged route Eligibility fails on the one-year requirement after the plan is set Check the clearance date at the outset and plan around full evaluation if it is short
Device mismatch against the reference clearance A question round comparing intended use, labelling and packaging Map the Thai device against the cleared device line by line before electing the abridged route
Classification settled late Reclassification mid-review restarts the dossier Obtain a written classification position before the technical file is built
Thin risk management file on full evaluation Repeated requests for information on the element the abridged route would have exempted Build the risk file to the standard a reviewer with no reference decision will demand
Thai labelling inconsistent with the dossier Claims in the instructions for use that the technical file does not support Translate and reconcile labelling against the dossier before filing, not after

What Lex Bangkok does on a Thailand medical device registration mandate

We act for foreign manufacturers and their distributors on the legal side of device entry: the structure that holds the registration, the classification determination, the pathway election, and the contractual terms that decide who owns the registration if the commercial relationship changes.

Stage What we do
Structure Establish the Thai entity that will hold the establishment licence, including the foreign ownership analysis where the group wants to control it directly
Classification Determine the risk class and the pathway in writing, and identify where a boundary question needs to be settled with the Medical Device Control Division
Pathway election Test eligibility for abridged or reliance treatment against the approvals actually held, and advise on sequencing where none qualifies
Establishment licence Prepare and file the establishment registration on the current form set, and address the facility requirements taking effect in May 2026
Dossier oversight Review the CSDT file for legal and regulatory sufficiency, and manage the response to Thai FDA questions
Distribution agreements Paper registration ownership, transfer on termination, regulatory responsibilities and liability allocation between manufacturer and Thai partner
Post-market Change notifications, renewals, vigilance obligations and advertising approval where the device will be promoted

Thailand medical device registration: frequently asked questions

Eligibility and routes

Can a device be registered in Thailand without a US FDA 510(k)?
Yes. A device without any reference-agency approval registers through the full evaluation route, submitting a complete CSDT technical file. Since 2024 the Thai FDA no longer requires reference-agency approval evidence for full evaluation, so the absence of a 510(k) is not a bar to registration.
How old must a 510(k) be to use the abridged route?
The abridged evaluation route requires the reference approval to have been in place for at least one year. A recently cleared device does not qualify until that period has passed, and for a Thailand-focused launch a full evaluation filed immediately is usually faster than waiting.
Which regulators does the Thai FDA recognise for the abridged route?
The recognised agencies include the US FDA, EU notified bodies, Australia’s TGA, Japan’s MHLW and Health Canada, together with WHO prequalification. Singapore’s HSA sits under a separate reliance route with its own conditions.

Structure and the licence holder

Can a foreign manufacturer hold a Thai registration directly?
No. Only a Thai national or an entity established in Thailand may hold the establishment licence, and the product registration is granted in the licence holder’s name. A foreign manufacturer that wants to control its own registration should establish a Thai entity rather than register through a distributor.
What happens to the registration if we change distributor?
The registration stays with the establishment licence holder. It does not follow the manufacturer automatically. Transfer mechanics should be agreed in the distribution agreement before appointment, because a distributor under notice has little incentive to cooperate afterwards.
How long are the licences valid?
Establishment licences are valid for five years, and product approvals are likewise granted on a five-year cycle. Renewal is an active obligation of the licence holder, alongside change notifications and post-market vigilance.

Dossier and process

What is the CSDT?
The Common Submission Dossier Template is the ASEAN-harmonised format for the technical file. Class 2, 3 and 4 devices must submit in this format, covering device description, risk analysis, verification and validation, clinical or performance evidence, quality system certification and labelling.
Is a Certificate of Free Sale still required?
The position is genuinely unsettled. Some guidance states the certificate was removed when documentation requirements were reduced; other sources continue to list it, and reviewers are reported to ask for market-authorisation evidence on higher-risk classes. Confirm the current requirement for your class before planning around its absence.
Does a Class 1 device get approved automatically?
Only if it appears on the Thai FDA Positive List, identified by GMDN code. Qualifying Class 1 professional-use devices have been auto-approved on submission since January 2025. A Class 1 device outside the Positive List follows the ordinary listing pathway.
Status of the law at 20 September 2026. The Medical Device Act B.E. 2551 (2008), as amended by the Medical Device Act (No. 2) B.E. 2562 (2019), is in force. The Good Manufacturing Practice B.E. 2566 (2023) and Good Importing and Sales Practice B.E. 2566 (2023) requirements are in force. The Thai FDA announcement on the registration of medical device manufacturing facilities was issued on 15 January 2026 and published in the Royal Gazette on 2 March 2026, taking effect in May 2026; the revised establishment registration forms are mandatory from 1 May 2026. Documentation requirements change frequently and published guidance is not always consistent, so confirm the current position for the specific class and device before filing. This article gives general information on Thai law, not advice on any particular matter, and creates no lawyer-client relationship.

Planning a device launch in Thailand

Lex Bangkok advises medical device manufacturers and their counsel on the legal side of Thai market entry: the entity that holds the establishment licence, the classification and pathway determination, eligibility for abridged or reliance treatment, and the distribution terms that decide who keeps the registration when a relationship ends. We also act where a registration sits with a former distributor and the manufacturer must recover or rebuild it. Where the device is a food, supplement or cosmetic rather than a medical device, we handle those under the Thai FDA registration and licensing practice, and the general process is set out in our Thailand FDA registration guide. Manufacturers intending to promote a registered device should read our note on medical advertising approval in Thailand before any campaign is built.

Arrange a Consultation

Primary sources: the Medical Device Act B.E. 2551 (2008) and the Medical Device Act (No. 2) B.E. 2562 (2019); the Thai Food and Drug Administration; and the ASEAN Medical Device Directive.